STOCK TITAN

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

TriSalus Life Sciences (NASDAQ: TLSI) reported strong financial results for Q4 and full-year 2024, with revenues reaching $8.3 million in Q4 and $29.4 million for the full year, showing growth of 44% and 59% respectively versus prior year periods. The company maintained impressive gross margins of 85% in Q4 and 86% for 2024.

Key developments include the launch of TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels, expanding their addressable market to $375 million. The company completed enrollment in the PERIO-03 Phase 1 trial for pancreatic cancer, with final data expected mid-2025.

For 2025, TriSalus reaffirmed guidance projecting over 50% revenue growth, more than 20% reduction in operating expenses, positive EBITDA, and positive cash flow in H2 2025. The company ended 2024 with $8.5 million in cash and expects sufficient runway throughout 2025.

TriSalus Life Sciences (NASDAQ: TLSI) ha riportato risultati finanziari solidi per il quarto trimestre e per l'intero anno 2024, con ricavi che hanno raggiunto 8,3 milioni di dollari nel Q4 e 29,4 milioni di dollari per l'intero anno, mostrando una crescita del 44% e del 59% rispettivamente rispetto ai periodi dell'anno precedente. L'azienda ha mantenuto margini lordi impressionanti dell'85% nel Q4 e dell'86% per il 2024.

Tra i principali sviluppi c'è il lancio del TriNav LV Infusion System e del TriGuide Guiding Catheter per vasi più grandi, espandendo il loro mercato indirizzabile a 375 milioni di dollari. L'azienda ha completato l'arruolamento nello studio clinico PERIO-03 di Fase 1 per il cancro pancreatico, con i dati finali previsti per metà 2025.

Per il 2025, TriSalus ha confermato le previsioni di una crescita dei ricavi di oltre il 50%, una riduzione di oltre il 20% delle spese operative, EBITDA positivo e flusso di cassa positivo nella seconda metà del 2025. L'azienda ha chiuso il 2024 con 8,5 milioni di dollari in contante e prevede di avere una sufficiente liquidità per tutto il 2025.

TriSalus Life Sciences (NASDAQ: TLSI) reportó resultados financieros sólidos para el cuarto trimestre y el año completo 2024, con ingresos que alcanzaron 8,3 millones de dólares en el Q4 y 29,4 millones de dólares para el año completo, mostrando un crecimiento del 44% y del 59% respectivamente en comparación con los períodos del año anterior. La empresa mantuvo márgenes brutos impresionantes del 85% en el Q4 y del 86% para 2024.

Los desarrollos clave incluyen el lanzamiento del TriNav LV Infusion System y el TriGuide Guiding Catheter para vasos más grandes, expandiendo su mercado direccionable a 375 millones de dólares. La empresa completó la inscripción en el ensayo PERIO-03 de Fase 1 para el cáncer de páncreas, con datos finales esperados para mediados de 2025.

Para 2025, TriSalus reafirmó su guía proyectando más del 50% de crecimiento en ingresos, más de un 20% de reducción en los gastos operativos, EBITDA positivo y flujo de caja positivo en la segunda mitad de 2025. La empresa terminó 2024 con 8,5 millones de dólares en efectivo y espera tener suficiente liquidez durante todo 2025.

TriSalus Life Sciences (NASDAQ: TLSI)는 2024년 4분기 및 전체 연도에 대한 강력한 재무 결과를 보고했으며, 4분기 수익은 830만 달러, 전체 연도 수익은 2,940만 달러에 달하며, 각각 전년 대비 44% 및 59%의 성장을 기록했습니다. 이 회사는 4분기 85%, 2024년 86%의 인상적인 총 마진을 유지했습니다.

주요 개발 사항으로는 더 큰 혈관을 위한 TriNav LV Infusion System 및 TriGuide Guiding Catheter의 출시가 있으며, 이로 인해 목표 시장이 3억 7,500만 달러로 확대되었습니다. 이 회사는 췌장암에 대한 PERIO-03 1상 시험의 등록을 완료했으며, 최종 데이터는 2025년 중반에 예상됩니다.

2025년을 위해 TriSalus는 50% 이상의 수익 성장, 운영 비용 20% 이상 절감, 긍정적인 EBITDA 및 2025년 하반기 긍정적인 현금 흐름을 예상한다고 재확인했습니다. 이 회사는 2024년을 850만 달러의 현금으로 마감했으며, 2025년 내내 충분한 자금을 확보할 것으로 예상합니다.

TriSalus Life Sciences (NASDAQ: TLSI) a rapporté de solides résultats financiers pour le quatrième trimestre et l'année complète 2024, avec des revenus atteignant 8,3 millions de dollars au Q4 et 29,4 millions de dollars pour l'année entière, affichant une croissance de 44 % et 59 % respectivement par rapport aux périodes de l'année précédente. L'entreprise a maintenu des marges brutes impressionnantes de 85 % au Q4 et de 86 % pour 2024.

Les développements clés incluent le lancement du TriNav LV Infusion System et du TriGuide Guiding Catheter pour des vaisseaux plus grands, élargissant leur marché adressable à 375 millions de dollars. L'entreprise a terminé le recrutement dans l'essai de phase 1 PERIO-03 pour le cancer du pancréas, avec des données finales attendues pour le milieu de 2025.

Pour 2025, TriSalus a réaffirmé ses prévisions, projetant une croissance des revenus de plus de 50 %, une réduction de plus de 20 % des dépenses d'exploitation, un EBITDA positif et un flux de trésorerie positif au second semestre 2025. L'entreprise a terminé 2024 avec 8,5 millions de dollars en liquidités et s'attend à disposer de suffisamment de liquidités tout au long de 2025.

TriSalus Life Sciences (NASDAQ: TLSI) hat starke Finanzzahlen für das vierte Quartal und das Gesamtjahr 2024 berichtet, mit Einnahmen von 8,3 Millionen Dollar im Q4 und 29,4 Millionen Dollar für das gesamte Jahr, was einem Wachstum von 44% bzw. 59% im Vergleich zu den Vorjahreszeiträumen entspricht. Das Unternehmen hielt beeindruckende Bruttomargen von 85% im Q4 und 86% für 2024 aufrecht.

Zu den wichtigsten Entwicklungen gehört die Einführung des TriNav LV Infusion System und des TriGuide Guiding Catheter für größere Gefäße, wodurch der adressierbare Markt auf 375 Millionen Dollar ausgeweitet wird. Das Unternehmen hat die Rekrutierung in die PERIO-03 Phase-1-Studie für Bauchspeicheldrüsenkrebs abgeschlossen, mit finalen Daten, die Mitte 2025 erwartet werden.

Für 2025 hat TriSalus die Prognose bekräftigt und geht von einem über 50%igen Umsatzwachstum, einer Reduzierung der Betriebskosten um mehr als 20%, positivem EBITDA und positivem Cashflow in der zweiten Jahreshälfte 2025 aus. Das Unternehmen beendete 2024 mit 8,5 Millionen Dollar in bar und erwartet, dass es während des gesamten Jahres 2025 über ausreichende Mittel verfügt.

Positive
  • Revenue growth of 59% YoY to $29.4M in 2024
  • Strong gross margins of 85-86%
  • Expanded product portfolio with TriNav LV and TriGuide launch
  • Secured $10M drawdown from $50M OrbiMed credit facility
  • Positive Phase 1 results in uveal melanoma liver metastases trial
Negative
  • Operating cash flow remained negative at -$5.7M in Q4 2024
  • Low cash position of $8.5M as of December 31, 2024
  • Delayed 10-K filing due to accounting errors in stock-based compensation
  • Required additional funding through credit facility drawdown

Insights

TriSalus Life Sciences' Q4 and full-year 2024 results demonstrate exceptional commercial momentum, with revenues reaching $29.4 million for the full year—a 59% increase from 2023. Q4 revenue of $8.3 million showed robust 44% growth compared to the same period last year. The 86% full-year gross margin indicates significant pricing power and production efficiency.

The company's aggressive 2025 financial targets deserve attention: projected revenue growth exceeding 50%, gross margin improvement to over 87%, and operating expense reduction exceeding 20%. Most crucially, management expects to achieve positive EBITDA for 2025 and cash flow positivity in H2, representing a pivotal inflection point toward sustainability.

The improving operating cash flow trend—from -$10.8 million to -$5.7 million quarter-over-quarter—supports management's financial projections. However, investors should note the accounting discrepancies flagged in the 10-K filing delay, creating some uncertainty around the finalized figures.

With a current market cap of approximately $166 million, TLSI trades at roughly 3.8x projected 2025 revenues (assuming 50% growth). This valuation appears modest for a company demonstrating accelerating growth, expanding margins, and approaching profitability. The secured $10 million drawdown from their credit facility helps mitigate near-term cash concerns.

TriSalus' product portfolio expansion with the TriNav LV Infusion System and TriGuide Guiding Catheter represents significant technological advancement with immediate revenue implications. By addressing vessels sized between 3.5-5.0mm, these devices effectively unlock the full $375 million liver embolization market previously not fully accessible to the company.

The DELIVER clinical program demonstrates strategic foresight by generating evidence to support PEDD technology adoption across broader therapeutic applications. The first PROTECT registry study targeting thyroid disease could add 50,000 procedures annually, representing a $400 million opportunity.

On the immunotherapy front, the completed enrollment in the PERIO-03 pancreatic cancer trial and the promising PERIO-01 trial results in uveal melanoma liver metastases position the company at the intersection of device and biologics innovation. The pursuit of strategic partnerships for the immunotherapy program is logical given the company's primary focus on device commercialization and the significant capital requirements for late-stage oncology trials.

The addition of board members with deep expertise in medical devices and oncology strengthens strategic oversight during this critical commercialization phase. The company's ability to maintain above-85% gross margins while scaling reflects strong intellectual property protection and manufacturing efficiency uncommon for early commercialization-stage medical technology companies.

  • Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods
  • Gross Margin of 85% and 86% for Q4 and Full-Year 2024
  • Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025
  • Management to host earnings conference call on March 27 at 8:00 a.m. EDT

DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.

“We achieved commercial and clinical progress throughout 2024, and positioning TriSalus for greater success in 2025,” said Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences. “We achieved $29.4 million in total revenue, marking 59% growth year-over-year, and continue to expect to deliver greater than 50% revenue growth in 2025. Additionally, we anticipate reducing operating expenses by more than 20%, achieving positive EBITDA for the full year, and achieving positive cash flow in the second half of the year.”

“We were also pleased to strengthen our Board of Directors with the additions of William Valle and Dr. Gary Gordon. Additionally, we want to sincerely thank Sean Murphy for his leadership in guiding the Company through the process of going public, a milestone that would not have been possible without his dedication and expertise. We are thrilled to welcome him back to the Board of Directors and look forward to his continued contributions to our success,” concluded Ms. Szela.

Clinical and Commercial Advancements

Expanded Product Portfolio

In the second half of 2024, TriSalus expanded its portfolio of PEDD devices with the launch of the TriNav LV Infusion System and TriGuide Guiding Catheter to optimize therapeutic delivery for patients with larger vessels. The TriNav LV is suitable for patients with vessels sized between 3.5 and 5.0mm. The TriGuide Guiding Catheter is equipped with a larger inner diameter, lubricious inner lining, and reverse curve design to support femoral access for the TriNav LV.

These new products are eligible for the same HCPCS reimbursement codes as existing TriNav products, which should enable seamless integration into current billing structures. The Company believes these expanded features will allow physicians to address more complex cases, enhance procedural efficiency, meaningfully expand its addressable market, and provide full access to the $375 million liver embolization market.

Expanding the DELIVER Clinical Program

The Company continues to advance its DELIVER clinical program, a series of Investigator Initiated Trials (IITs) designed to further underscore the impact of PEDD technology by demonstrating enhanced safety and efficacy of the TriNav system across a broad spectrum of complex, difficult-to-treat patients. A key focus of the DELIVER program is to investigate the potential of combining use of the TriNav system with other therapies to enhance effectiveness and address resistance mechanisms in challenging cancers.

The first IIT is a registry study called PROTECT (Pressure Enabled Retrograde Occlusive Therapy with Embolization for Control of Thyroid Disease). The PROTECT study has been initiated and intends to enroll 100 patients across five leading academic sites. It is estimated that approximately 5% of adults have multinodular goiters, prevalence in adults over 50 is estimated to be up to 50%. The Company estimates that this may expand the addressable market by approximately 50,000 procedures, representing an incremental $400 million market opportunity and putting the Company’s total addressable market at more than $1 billion.

Advancing Pancreatic Cancer Treatment – Enrollment was completed in the PERIO-03 Phase 1 trial investigating nelitolimod in locally advanced pancreatic cancer. Final data are expected mid-2025, with next steps to be determined based on results.

Clinical Progress in Immunotherapy – In November 2024, we presented positive Phase 1 results from our PERIO-01 trial at the Society for Immunotherapy of Cancer (SITC), demonstrating promising clinical benefits and durable survival in heavily pretreated uveal melanoma liver metastases (UM-LM) patients. We are actively seeking strategic partnerships to advance this program.

Strengthened Board and Financial Position

New Board Members – Industry veterans William Valle and Dr. Gary Gordon joined the Board of Directors, bringing deep expertise in medical devices and oncology. Additionally, Sean Murphy retired from the management team and rejoined the Board.

Extended Cash Runway – TriSalus secured a $10 million drawdown under its existing $50 million credit facility with OrbiMed, ensuring financial flexibility through the end of 2025.

Unaudited Financial Results for Fourth Quarter and Full Year 2024

The Company will file a Form 12b-25, Notification of Late Filing, with the SEC related to the Company’s Annual Report on Form 10-K for fiscal year 2024. The Company’s need to request a 15-day extension is primarily due to errors identified in determining the Company’s stock-based compensation and clinical trial related research and development expense timing in 2024. The Company is working diligently to evaluate the materiality of the errors to determine whether any corrections for previously issued quarterly financial statements are required and to complete the Company’s year end 2024 financial statements. As a result, the results below and elsewhere in this press release are unaudited and subject to change pending the completion of the Company’s financial statement as of and for the year ended December 31, 2024.

Full year 2024 revenue was $29.4 million, representing growth of approximately 59% versus the full year 2023. Momentum in revenue growth is expected to continue in 2025 and, consistent with previously announced guidance, is expected to grow in excess of 50% in 2025.

Operating Cash Flow in the fourth quarter of 2024 was ($5.7) million, reflecting a notable improvement compared to the previous quarter amount of ($10.8) million. Consistent with previously announced guidance, the Company expects to achieve positive full year EBITDA in 2025 and positive cash flow during the second half of 2025.

Cash and Cash Equivalents were $8.5 million as of December 31st, 2024. The Company expects existing liquidity sources and the $15 million of available capacity on the OrbiMed debt facility to provide sufficient cash runway throughout 2025.

2025 Guidance

The company is reaffirming previously issued guidance for 2025, including:

  • Sales are expected to grow by more than 50% in 2025, driven by further market share increases in TriNav, the commercial launch of TriNav LV, and the TriNav target market expansion driven by the DELIVER program and the new HCPCS reimbursement code for TriNav simulation angiograms —commonly known as mapping procedures—conducted prior to transarterial radioembolization (TARE) from Centers for Medicare & Medicaid Services (CMS).
  • Gross margins are expected to exceed 87%.
  • Operating expenses are expected to decline greater than 20% in 2025 due to reductions in R&D associated with the completion of the PERIO phase 1b trials and reductions in G&A expenses due to the non-recurrence of certain costs related to becoming a public Company in 2024.
  • The company expects to be EBITDA positive for 2025 and achieve positive cash flow by the second half of 2025, extending total cash runway beyond 2025.

Conference Call

The company will host a conference call and webcast on March 27, 2025, at 8:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update. A press release detailing the fourth quarter and full year results will be issued prior to the call. To register for the webcast, click here.

About TriSalus Life Sciences

TriSalus Life Sciences® is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. Nelitolimod delivered by the PEDD technology will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on Twitter and LinkedIn.

Forward Looking Statements

Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company’s PEDD drug delivery technology, TriNav system and nelitolimod investigational immunotherapy, the expected timing for reporting results from the Company’s clinical trials for nelitolimod, the Company’s expectation that the development of nelitolimod for the indications covered by PERIO-02 will continue through investigator led trials, the Company’s ability to achieve the revenue milestones under the credit facility, the Company’s expectations about its cash runway, the Company’s expectations about its revenue growth for 2024, the expected benefits from the Company’s DELIVER program, the Company’s expected timing to launch PROTECT study and any future studies, and the Company’s ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company’s clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company’s ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company’s filings with the Securities and Exchange Commission under the heading "Risk Factors." All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.

 

TriSalus Life Sciences

 
Consolidated Statement of Operations (unaudited, in thousands)
 

Three Months Ended

 

Twelve Months Ended

December 31,

 

December 31,

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue

$

8,261

 

$

5,721

 

$

29,431

 

$

18,511

 

Cost of goods sold

 

1,216

 

 

582

 

 

4,103

 

 

2,605

 

Gross Profit

 

7,045

 

 

5,139

 

 

25,328

 

 

15,906

 

Operating expenses:
Research and development

 

2,959

 

 

7,769

 

 

17,688

 

 

29,835

 

Sales and marketing

 

7,010

 

 

5,604

 

 

25,839

 

 

17,034

 

General and administrative

 

4,656

 

 

6,014

 

 

17,966

 

 

23,512

 

Loss from operations

 

(7,580

)

 

(14,248

)

 

(36,165

)

 

(54,475

)

Interest income

 

57

 

 

244

 

 

404

 

 

431

 

Interest expense

 

(1,068

)

 

(3

)

 

(3,090

)

 

(16

)

Loss on equity issuance

 

(183

)

 

(5,874

)

Extinguishment of tranche liability

 

1,520

 

Change in fair value of warrant, SEPA and revenue base redemption liabilities

 

(586

)

 

(11,515

)

 

(2,107

)

 

(10,855

)

Change in fair value of contingent earnout liability

 

(830

)

 

(9,611

)

 

11,231

 

 

10,293

 

Other expense, net

 

(102

)

 

(323

)

 

(312

)

 

(379

)

Loss before income taxes

 

(10,109

)

 

(35,639

)

 

(30,039

)

 

(59,355

)

Income tax expense

 

1

 

 

(1

)

 

(6

)

 

(9

)

Net loss available to common stockholders

$

(10,108

)

$

(35,640

)

$

(30,045

)

$

(59,364

)

Deemed dividend related to Series B-2 preferred stock down round provision

 

(2,981

)

Undeclared dividends on Series A preferred stock

 

(783

)

 

(800

)

 

(3,188

)

 

(1,258

)

Net loss attributable to common stockholders

$

(10,891

)

$

(36,440

)

$

(33,233

)

$

(63,603

)

Net loss per common share, basic and diluted

$

(0.40

)

$

(1.57

)

$

(1.31

)

$

(6.77

)

Weighted average common shares outstanding, basic and diluted

 

27,551,189

 

 

23,231,975

 

 

25,331,753

 

 

9,395,748

 

 
TriSalus Life Sciences
 
Consolidated Balance Sheets (unaudited, in thousands)
 

December 31,

 

December 31,

2024

 

2023

Assets
Assets
Cash and cash equivalents

8,525

 

11,777

 

Accounts receivable

5,087

 

3,554

 

Inventory, net

4,048

 

2,545

 

Prepaid expenses

3,009

 

2,986

 

Total current assets

20,669

 

20,862

 

Property and equipment, net

1,669

 

2,091

 

Right-of-use assets

1,210

 

1,179

 

Other assets

423

 

466

 

Total assets

23,971

 

24,598

 

Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
Trade payables

2,274

 

3,391

 

Accrued liabilities

7,355

 

10,556

 

Short-term lease liabilities

216

 

351

 

Other current liabilities

383

 

389

 

Total current liabilities

10,228

 

14,687

 

Long-term debt, net of unamortized discount and debt issuance costs

22,084

 

Revenue base redemption liability

507

 

Long-term lease liabilities

1,329

 

1,244

 

Contingent earnout liability

7,401

 

18,632

 

Warrant and SEPA liabilities

8,316

 

17,100

 

Total liabilities

49,865

 

51,663

 

Stockholders' deficit:
Preferred Stock, Convertible preferred stock, Series A $0.0001 par value per share,
$10 liquidation value per share. Authorized 10,000,000 shares at December 31, 2024
and 2023, respectively; issued and outstanding, 3,985,002 and 4,015,002 shares at
December 31, 2024 and 2023, respectively
Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at
December 31, 2024 and 2023, respectively; issued and outstanding 31,279,264 shares
and 26,413,213 shares at December 31, 2024 and 2023, respectively

3

 

2

 

Additional paid-in capital

253,652

 

222,437

 

Accumulated deficit

(279,549

)

(249,504

)

Total stockholders' deficit

(25,894

)

(27,065

)

Total liabilities, convertible preferred stock and stockholders' deficit

23,971

 

24,598

 

 

For Media Inquiries:

Jeremy Feffer, Managing Director

LifeSci Advisors

917.749.1494

jfeffer@lifesciadvisors.com

For Investor Inquiries:

James Young

Chief Financial Officer

847.337.0655

james.young@trisaluslifesci.com

Source: TriSalus Life Sciences

FAQ

What was TriSalus Life Sciences (TLSI) revenue growth in 2024?

TLSI reported revenue of $29.4M in 2024, representing 59% growth compared to 2023, with Q4 revenue of $8.3M showing 44% growth.

How much cash does TLSI have and is it sufficient for 2025?

TLSI had $8.5M cash as of December 31, 2024, with $15M available credit facility capacity, which management expects will provide sufficient runway throughout 2025.

What are TLSI's financial targets for 2025?

TLSI expects >50% revenue growth, >20% reduction in operating expenses, positive EBITDA for full year, and positive cash flow in H2 2025.

What new products did TLSI launch in 2024?

TLSI launched the TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels, expanding their addressable market to $375M.

When will TLSI's PERIO-03 pancreatic cancer trial data be available?

Final data from the PERIO-03 Phase 1 trial in pancreatic cancer is expected by mid-2025.
TriSalus Life Sciences Inc.

NASDAQ:TLSI

TLSI Rankings

TLSI Latest News

TLSI Stock Data

172.66M
13.67M
54.94%
13.12%
0.45%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
WESTMINSTER